Medicaid

Five things for pharma marketers to know: Thursday, November 10, 2016

Five things for pharma marketers to know: Thursday, November 10, 2016

By

Mylan reports third-quarter loss; analysts say drug-pricing restrictions less likely under Trump; the FDA limits citizen petitions

Developers should consider products that serve the underserved, report finds

Developers should consider products that serve the underserved, report finds

By

Digital health technology for low-income consumers is growing and can be very effective when applied appropriately, a report finds.

Five things for pharma marketers to know: Friday, November 6, 2015

Five things for pharma marketers to know: Friday, November 6, 2015

By

Obama administration tells states they cannot restrict hep-C drugs; AstraZeneca says it will acquire ZS Pharma: Allergan CEO says drug discovery is too risky

Five things for pharma marketers to know: Wednesday, August 26

Five things for pharma marketers to know: Wednesday, August 26

By

Medicaid officials urged to expand access to hepatitis-C drugs; Perrigo is looking to make acquisitions; Sarepta's experimental therapy gets priority review

Study: 10 medications will cost US $50 billion over 10 years

Study: 10 medications will cost US $50 billion over 10 years

By

An analysis by Avalere Health says 10 breakthrough therapy drugs will account for billions in spending.

 Five things for pharma marketers to know: Thursday, April 9

Five things for pharma marketers to know: Thursday, April 9

By

Novartis reported highest drug sales in 2014; state Medicaid programs spent $1.33 billion on hepatitis-C drugs; former FDA commissioner argues against shortening regulatory review times

Opinion

How to Shatter the Glass Ceiling

How Pharma Can Benefit from the Transformation of Pharmacy

Newsletters

Live at MM&M Transforming Healthcare

Pharma faces its 'oh, shit' moment

In his keynote address at the MM&M Transforming Healthcare conference, Dr. Gautam Gulati says the industry is being outpaced by its innovation.

Merck, Takeda execs: Is AI the new bad app?

One executive referred to AI as a "black box" and as the "Tower of Babel."

Value-based care requires innovators to challenge the status quo

Execs stressed the importance of collaboration, consumer-mindedness.

Admetsys wins the 2017 MM&M Startup Showdown

The artificial pancreas can provide value to the health system.

Top 40 Healthcare Transformers

MM&M honors 40 upstarts and veteran innovation gurus.

Top 10 Innovation Catalysts

For the first time MM&M honors a group of 10 agency execs.